Glenmark Pharmaceuticals has submitted a new drug application with the US health regulator for its nasal spray Ryaltris.
Ryaltris is for treatment of seasonal allergic rhinitis (SAR) in patients 12 years of age and older.
"The company has submitted a new drug application (NDA) to the US Food & Drug Administration (USFDA) for... respiratory pipeline candidate Ryaltris, an investigational fixed-dose combination nasal spray of an antihistamine and a steroid," Glenmark Pharmaceuticals said in a BSE filing.
Ryaltris (olopatadine hydrochloride (665 mcg) and mometasone furoate (25 mcg)), formerly GSP 301 Nasal Spray, has been conditionally accepted by the USFDA as the brand name, the company added.
Glenmark said it expects the USFDA will determine whether the NDA is complete for filing within 60 days.
"If the NDA is accepted, the Prescription Drug User Fee Act (PDUFA) target action date will be assigned at that time," it added.
Glenmark has studied Ryaltris in seven clinical trials involving more than 4,000 patients.
Shares of Glenmark Pharmaceuticals were trading 0.36 per cent higher at Rs 502.65 on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app